aCGH Impacts Survival in Plasma Cell PTLD

Completed

• Conditions: Post-transplantation Lymphoproliferative Disorders

• Registration Number: NCT02984215
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Plasma-cell post-transplantation lymphoproliferative disorders (PC-PTLD) are rare monomorphic PTLD divided into plasma cell myeloma (PCM) and plasmacytoma-like lesion (PLL) PTLD. To date, there is no exhaustive published cytogenetic data on PC-PTLD. The investigators report array-based comparative genomic hybridization (aCGH) of 10 cases of PCM and PLL-PTLD.

Detailed Description

Not available

Study Timeline

• Study Start: 1990-01
• Primary Completion: 2012-01
• Study Completion: 2016-06
• Status Verified: 2016-10
• Study First Submitted: 2016-10-31
• Study First Submitted QC: 2016-12-02
• Last Update Submitted: 2016-12-02
• Study First Posted: 2016-12-06
• Last Update Posted: 2016-12-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• WHO classification 2008 as monomorphic PCM (plasma cell myeloma) or PLL (plasmacytoma like lesion) / PTLD (post transplantation lymphoproliferative disorders).

Read More

Exclusion Criteria

• Other than PCM or PLL PTLD at diagnosis

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Genome wide array-based comparative genomic hybridization (aCGH)	At diagnosis of PTLD, Day 0.

Secondary Outcome Measures

Name	Time	Method
Overall survival according to aCGH complexity	Overall survival (OS) was calculated from date of diagnosis to date of death from any cause, up to 130 months.

Trial Locations

Locations (1)

Centre hospitalier Lyon sud; 🇫🇷 Pierre Bénite, Rhône Alpes, France